Literature DB >> 9321761

Uptake of genetic testing for cancer predisposition.

D G Evans1, E R Maher, R Macleod, D R Davies, D Craufurd.   

Abstract

Although there has been much debate about the uptake and effects of predictive testing for common cancers, such as breast and colon cancer, little has been published on the more classical tumour predisposing conditions, such as von Hippel-Lindau disease and familial adenomatous polyposis. Since 1990 the genetics departments in Manchester and Cambridge have had a genetic register for cancer predisposing syndromes and presymptomatic testing for these conditions has been offered once this has become possible. To investigate the factors that might influence uptake of genetic testing in familial cancer syndromes we have reviewed our experience. Demand for predictive testing has generally been high, but men had a lower uptake (77%) than a comparable group of women (93%) (p < 0.01).

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9321761      PMCID: PMC1051059          DOI: 10.1136/jmg.34.9.746

Source DB:  PubMed          Journal:  J Med Genet        ISSN: 0022-2593            Impact factor:   6.318


  11 in total

1.  Predictive diagnosis of familial adenomatous polyposis with linked DNA markers: population based study.

Authors:  F MacDonald; D G Morton; P M Rindl; J Haydon; R Cullen; J Gibson; J P Neoptolemos; M R Keighley; C M McKeown; M Hultén
Journal:  BMJ       Date:  1992-04-04

2.  Uptake of presymptomatic predictive testing for Huntington's disease.

Authors:  D Craufurd; A Dodge; L Kerzin-Storrar; R Harris
Journal:  Lancet       Date:  1989-09-09       Impact factor: 79.321

3.  Von Recklinghausen neurofibromatosis. A clinical and population study in south-east Wales.

Authors:  S M Huson; P S Harper; D A Compston
Journal:  Brain       Date:  1988-12       Impact factor: 13.501

4.  Testing for cancer genes: decisions, decisions.

Authors:  K A Schneider; A F Patenaude; J E Garber
Journal:  Nat Med       Date:  1995-04       Impact factor: 53.440

5.  Non-penetrance and late appearance of polyps in families with familial adenomatous polyposis.

Authors:  D G Evans; S P Guy; N Thakker; J G Armstrong; C Dodd; D R Davies; C Babbs; T Clancy; T Warnes; P Sloan
Journal:  Gut       Date:  1993-10       Impact factor: 23.059

6.  Insurance and genetic testing.

Authors:  P S Harper
Journal:  Lancet       Date:  1993-01-23       Impact factor: 79.321

7.  DNA screening for breast/ovarian cancer susceptibility based on linked markers. A family study.

Authors:  H T Lynch; P Watson; T A Conway; J F Lynch; S M Slominski-Caster; S A Narod; J Feunteun; G Lenoir
Journal:  Arch Intern Med       Date:  1993-09-13

8.  Von Hippel-Lindau disease: a genetic study.

Authors:  E R Maher; L Iselius; J R Yates; M Littler; C Benjamin; R Harris; J Sampson; A Williams; M A Ferguson-Smith; N Morton
Journal:  J Med Genet       Date:  1991-07       Impact factor: 6.318

9.  A clinical study of type 2 neurofibromatosis.

Authors:  D G Evans; S M Huson; D Donnai; W Neary; V Blair; V Newton; R Harris
Journal:  Q J Med       Date:  1992-08

10.  Anticipated uptake and impact of genetic testing in hereditary breast and ovarian cancer families.

Authors:  J P Struewing; C Lerman; R G Kase; T R Giambarresi; M A Tucker
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  1995-03       Impact factor: 4.254

View more
  13 in total

Review 1.  Integrated regional genetic services: current and future provision.

Authors:  D Donnai; R Elles
Journal:  BMJ       Date:  2001-04-28

2.  Tensions in implementing the new genetics. General practitioners in south Wales are unconvinced of their role in genetics services.

Authors:  G Elwyn; J Gray; R Iredale
Journal:  BMJ       Date:  2000-07-22

Review 3.  The new genetics. Psychological responses to genetic testing.

Authors:  T M Marteau; R T Croyle
Journal:  BMJ       Date:  1998-02-28

4.  Comparison of genetic services with and without genetic registers: knowledge, adjustment, and attitudes about genetic counselling among probands referred to three genetic clinics.

Authors:  C Wright; L Kerzin-Storrar; P R Williamson; A Fryer; A Njindou; O Quarrell; D Donnai; D Craufurd
Journal:  J Med Genet       Date:  2002-12       Impact factor: 6.318

Review 5.  Neurofibromatosis type 2.

Authors:  D G Evans; M Sainio; M E Baser
Journal:  J Med Genet       Date:  2000-12       Impact factor: 6.318

6.  Uptake of Predictive Genetic Testing and Cardiac Evaluation for Children at Risk for an Inherited Arrhythmia or Cardiomyopathy.

Authors:  Susan Christian; Joseph Atallah; Robin Clegg; Michael Giuffre; Cathleen Huculak; Tara Dzwiniel; Jillian Parboosingh; Sherryl Taylor; Martin Somerville
Journal:  J Genet Couns       Date:  2017-07-11       Impact factor: 2.537

7.  Paediatric presentation of type 2 neurofibromatosis.

Authors:  D G Evans; J M Birch; R T Ramsden
Journal:  Arch Dis Child       Date:  1999-12       Impact factor: 3.791

8.  Ten years of presymptomatic testing for Huntington's disease: the experience of the UK Huntington's Disease Prediction Consortium.

Authors:  P S Harper; C Lim; D Craufurd
Journal:  J Med Genet       Date:  2000-08       Impact factor: 6.318

9.  Childhood predictive genetic testing for Li-Fraumeni syndrome.

Authors:  D G Evans; P Lunt; T Clancy; R Eeles
Journal:  Fam Cancer       Date:  2009-04-30       Impact factor: 2.375

10.  Uptake of genetic testing and long-term tumor surveillance in von Hippel-Lindau disease.

Authors:  Astrid Rasmussen; Elisa Alonso; Adriana Ochoa; Irene De Biase; Itziar Familiar; Petra Yescas; Ana-Luisa Sosa; Yaneth Rodríguez; Mireya Chávez; Marisol López-López; Sanjay I Bidichandani
Journal:  BMC Med Genet       Date:  2010-01-12       Impact factor: 2.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.